The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment

The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with bortezomib (VMP), with thalidomide (MPT), and with lenalidomide with (MPR-R...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Garrison, Louis P., Wang, Si-Tien, Huang, Hui, Ba-Mancini, Abbie, Shi, Hongliang, Chen, Kristina, Korves, Caroline, Dhawan, Ravinder, Cakana, Andrew, van de Velde, Helgi, Corzo, Deyanira, Duh, Mei Sheng
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2013
Assuntos:
Economics of Oncology Practice
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3556252/
https://ncbi.nlm.nih.gov/pubmed/23299777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0380
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados